purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation dxcm earnings call period ending december image source motley fool dexcom dxcm q earnings callfeb pm etcontents prepared remark question answer call participant prepared remark operatorladies gentleman welcome dexcom fourth quarter fiscal year earnings conference call name abby operator today call time participant listenonly mode later conduct questionandanswer session operator instruction reminder conference recorded turn call sean christensen vice president finance investor relation may beginsean christensen head investor relation thank abby welcome dexcoms fourth quarter fiscal year earnings call agenda begin kevin sayer dexcoms chairman president ceo summarize recent highlight ongoing strategic initiative followed financial review outlook jereme sylvain chief financial officer following prepared remark open call question time ask analyst limit one question provide opportunity everyone participating today please note also slide available related fourth quarter fiscal year performance dexcom investor relation website event presentation page let u review safe harbor statement statement make today call may constitute forwardlooking statement statement reflect management intention belief expectation future event strategy competition product operating plan performanceshould invest dexcom right buy stock dexcom consider motley fool stock advisor analyst team identified believe best stock investor buy dexcom one stock made cut could produce monster return coming year stock advisor provides investor easytofollow blueprint success including guidance building portfolio regular update analyst two new stock pick month stock advisor service tripled return sp since see stock stock advisor return february forwardlooking statement included presentation made date hereof based information currently available dexcom subject various risk uncertainty actual result could differ materially anticipated forwardlooking statement factor could cause actual result differ materially expressed implied forwardlooking statement detailed dexcoms annual report form k recent quarterly report form q filing security exchange commission except required law assume obligation update forwardlooking statement date presentation conform forwardlooking statement actual result additionally call discus certain financial measure prepared accordance gaap respect nongaap cashbased result unless otherwise noted reference financial metric presented nongaap basis presentation additional information considered isolation substitute result superior result prepared accordance gaap please refer table earnings release slide accompanying fourth quarter fiscal year earnings presentation reconciliation measure directly comparable gaap financial measure turn kevin kevin sayer chairman president chief executive officer thank sean thank everyone joining u incredible year dexcom would like start reviewing key accomplishment total revenue grew organic basis driven another year record customer start translates million organic revenue growth compared last year built strong commercial momentum recent coverage expansion performance dexcoms cgm system added dexcom user base ended year approximately million customer globally importantly delivered level growth enhancing scale efficiency operation key milestone opening malaysia manufacturing facility around midyear production site ramping quickly team already delivering yield par established yous facility facility help support growth cost ambition year come measure success generated billion q revenue also delivered billion adjusted ebitda year generated record level free cash flow nearly compared establishing disciplined cost culture focus year advance striking right balance margin progression still investing strategically pathway support significant growth opportunity strategic perspective go one transformational year company history launched g dexcom one multiple new market significantly expanding global access advancing key technical clinical work provide foundation future dexcom started rollout g yous february g accurate cgm ever launched market reception g exceptional customer clinician thrilled new form factor product performance ease use payer wasted time establishing coverage recognize clear value proposition g provides immediately started see change prescribing pattern product reached market trend became even pronounced completed largest expansion coverage company history midapril medicare coverage went live people type diabetes using basal insulin well certain noninsulinusing individual hypoglycemia risk decision broad commercial coverage quickly followed basal market effectively doubled reimbursed population yous completely changed market landscape yous broader coverage available new product greatly simplifies prescribing process attracted sizable new cohort clinician ecosystem fact expanded prescriber base approximately stopping always known primary care channel would become increasingly important business evolves much work commercial team done recent year tailored market seeing direct result effort new script written primary care physician relationship critical help u reach million insulinusing individual yet started cgm also ten million broader type diabetes prediabetes beyond based success team magnitude future opportunity excited continue investment yous sale force year presence prescribers win u continue expand prescriber pool already seeing clinician want incorporate dexcom cgm earlier patient care plan recognize unique ability drive behavior change sustainable outcome greater accountability thrilled introducing newest product stelo later summer stelo first cgm designed specifically people type diabetes insulin leveraging leading sensor platform built custom software experience tailored need population stelo feature day wear time launch cash pay product build case payer broader coverage several trial currently underway continue add growing body evidence demonstrating dexcoms unique ability drive greater health economic outcome people diabetes launch stelo also present great opportunity bolster evidence large collection realworld data see impact product customer filed stelo fda fourth quarter leaving u well track highly anticipated launch summer product portfolio continues grow provides greater glimpse future potential company built platform technology customize provide creative solution different population redesigned software infrastructure key component enables much quicker iteration greater connectivity connectivity always distinct advantage dexcom recent filing directtowatch fda new g pump integration advancing leadership position also continue innovating hardware technology current effort focused launching extended wear sensor across product offering look significant opportunity ahead u excited ever said investor day past summer getting started turn jereme review fourthquarter financials jeremejereme sylvain chief financial officer thank kevin reminder unless otherwise noted financial metric presented today discussed nongaap basis reconciliation gaap found today earnings release well ir website fourth quarter reported worldwide revenue billion compared million fourth quarter representing growth reported basis organic basis reminder definition organic revenue excludes currency addition noncgm revenue acquired divested trailing month yous revenue totaled million fourth quarter compared million fourth quarter representing growth ongoing success g significantly improved access recent month momentum yous business continues grow fact delivered fastest quarterly yous growth rate since beginning revenue accelerated third quarter row international revenue grew totaling million fourth quarter international organic revenue growth fourth quarter continue execute well across international footprint took share q global access work product portfolio strategy helped broaden reach many market fourthquarter gross profit million revenue compared revenue fourth quarter yearoveryear decline gross margin expected g much larger percent product customer mix q compared year ago reminder g higher cost profile g today expect change coming quarter drive greater volume g line reach scale continue expect g margin profile improve upon g platform operating expense million q compared million q quarter another demonstration commitment disciplined thoughtful spend operating expense grew half rate revenue quarter delivered nearly basis point operating expense leverage compared last year extended streak eight straight quarter least basis point yearoveryear opex leverage operating income million revenue fourth quarter compared million revenue quarter adjusted ebitda million revenue fourth quarter compared million revenue fourth quarter net income third quarter million per share remain great financial position closing year greater billion cash cash equivalent financial flexibility allows organization take advantage opportunity case point executed million accelerated share repurchase program mentioned q result transaction able offset remaining dilution related maturing convert purchasing stock view attractive price kevin mentioned earlier free cash flow grew business continues scale become efficient cash flow profile continues grow add significant financial flexibility allows u continue invest behind meaningful organic growth opportunity assessing strategic us capital ongoing basis turning guidance stated last month anticipate total revenue range billion billion representing organic growth year guidance assumes continued momentum type basalonly population yous expansion dexcom one g platform new geography launch stelo summer also assumes divestiture nondiabetes distribution business australia new zealand quarter represented around million revenue margin perspective expect fullyear nongaap gross profit margin range operating profit margin approximately adjusted ebitda approximately gross margin guidance reflects ongoing conversion g g within customer base associated scale come process gross margin continue diligent spend investing strategically behind multiple growth opportunity pas back kevinkevin sayer chairman president chief executive officer thanks jereme would like open call qa seansean christensen head investor relation thank kevin reminder ask audience limit one question time reenter queue necessary abby please provide qa instruction question answer operatorthank well begin questionandanswer session operator instruction take first question robbie marcus jpmorgan line openrobbie marcus jpmorgan chase company analyst great offer second time congrats really good quarter wanted tie two idea together first great operating margin saw fourth quarter came well street slide deck presentation slide making progress day sensor question really one update time frame gseries day sensor approved really think could take good operating margin put guided next year could really take future thankskevin sayer chairman president chief executive officer thanks robbie kevin take day sensor timing jereme talk number effect operating margin going forward said earlier year middle clinical testing scientific evaluation fundamental science change sensor make reliable day period one reason done well two thing accuracy sensor performance sensor time combined fact people expect get certain amount day sensor deliver tell going want make sure day experience every bit good day experience offer making slight change science basis run clinical study file certainly would expect get approved right still evaluating technology really provide lot color filed see path toward approvaljereme sylvain chief financial officer yeah question longer term operating margin done really nice job date creating leverage opportunity within operating margin profile despite move channel mix change made top line able maintain gross margin based lot work done around design value lot scale able achieve think day provides real big opportunity u think leverage gross margin operating margin profile also opportunity grow business area profitably maybe would little bit challenge day product absolutely effort going organization provide u lot flexibility either continue grow business b deliver operating margin worldclass time think longer term lot opportunity ready particularly lay obviously given lrp execute think provides real longterm opportunity company deliver back shareholder take advantage opportunity globallyoperatorwe take next question danielle antalffy ubs line opendanielle antalffy ubs analyst hi good afternoon everyone thanks much taking question congrats really strong end year great see going ask question hearing potential competition coming market would love kevin maybe could highlight u competitive moat dexcom built obviously know much competitor planning bring market maybe could highlight think dexcom competition perspective defensible share thanks muchkevin sayer chairman president chief executive officer well appreciate question first foremost start core technology fundamental belief company performance center unparalleled got million year example aid system great outcome patient done well built platform connectivity one feature talked engineer kind complained took lot time engineer connect three device time type connectivity competitor put platform feature important patient reason example filed directtowatch feature fda one thing competition think look u today think going stay certainly new pipeline effort across front technology side better connectivity communication software investment evolve literally medical device software company worldclass software organization past couple year evolution u big investment looked area invest make stronger made investment technology side piece spent hundred million dollar past three year getting fully automated factory running united state new factory malaysia opened midyear tremendous facility built automated line turned ground next worldclass factory ireland would open huge investment made play cgm business going forward particularly scale performance see made investment done thing evolved company think well positioned see everybody else come comfortable well let rephrase never comfortable believe done right thingsoperatorand take next question larry biegelsen well fargo line openlarry biegelsen well fargo security analyst good afternoon thanks taking question yeah wanted focus stelo expect product add approximately think basis point growth almost million six month pretty healthy number half year kevin informing confidence launch big could product time margin implication thank youkevin sayer chairman president chief executive officer larry thanks question guided purpose launch get product learn look revenue number certainly model build support believe designing product type noninsulin user others targeting right segment go important experience stelo learning getting starting develop grow new market confident product time become large portion business large segment within market year launch learning anything else model would love exceed learn lesson need learn backbreaker company guidance either important thing get product learn anything elsejereme sylvain chief financial officer yeah question margin necessarily talking gross margin perspective come time start release detail around larry operating margin yes something going invest think overall company margin certainly invest invest launching sale marketing investment going make year going make investment product believe future going still expand operating margin company safe going careful measured invest dollar know part investment set aside organization still improving profitabilityoperatorwe take next question mathew blackman stifel line openmathew blackman stifel financial corp analyst great appreciate taking question maybe kevin jereme obviously mentioned sale force pcp channel remind u least today kind pcp sale force coverage importantly sort leaning comment kevin investing seemingly incrementally channel year mean term spend magnitude spend timing much coverage expecting add investment way frame trying accomplish thank youjereme sylvain chief financial officer yeah thanks question matt think investment going expand sale force today good amount coverage ten thousand primary care physician predominantly entirety endocrinologist space start think basal coverage expanding opportunity ahead u certainly stelo horizon found opportunity continue expand know cgm specifically dexcom cgm play important role folk manage diabetes know call point helpful going expand take look linkedin amount quite opening term size expand sale force get coverage term cadence linkedin recs right see u hire course first quarter obviously fully loaded burden associated rep take place back half year q q think cadence contemplated overall guidance provided operating margin expect part typical work around creating leverage business investing need thinking cadence course year expect hire made course first quarter folk ramp part run rate really q balance yearoperatorand take next question marie thibault btig line openmarie thibault btig analyst thanks good evening thanks taking question wanted ask question international think reminded u selling noncgm business australia also going direct japan wanted understand cadence q versus rest year also sort comment could make g dexcom one platform allaround international question therejereme sylvain chief financial officer sure thanks marie give context noncgm business effectively gone point comfortable pulling talking organic quarter expect talked ish million last year math kind allocation quarter point part think quarter japan certainly similar type thing talked q effectively nil would expect similar contribution first quarter start take book business business live second quarter expect start contribute build business back course year really international kind timing q heaviest burden term transition pertains dexcom one g great news think press released couple day ago four country launched come today four country first foray getting great feedback early adopter within country expectation cadence launch dexcom one g form factor really course year would expect lot press release around launching expect really take place course year give u lot confidence dexcom one really incredible growth driver long termoperatorwe take next question jeff johnson baird line openjeff johnson robert w baird company analyst hey guy good afternoon maybe keep international point think first quarter seen international growth yous growth look back last quarter think gone organic growth rate help u understand kind international versus yous growth might settle would expect similar international continue slow reason think competitive aid approval happened europe especially one competitive cgm thinking stability maybe installed base aid side versus win rate new aid system thank youjereme sylvain chief financial officer sure hey thanks jeff think cadence thanks question international think cadence course year certainly q buoyed different way guess would say different thing talked little bit earlier japan business really revenue effectively nil make transition negative grower quarter nondiabetes business really flat think business historically pretty significant grower pull start exclude thing still growing quite well fact core business operate today youk germany australia etc continue grow relatively consistently q q q ebb flow part well think mean going forward changed stance ous business international business percentage revenue end bigger today twothirdsonethird split today like think whole expect international business opportunity certainly underpenetration today grow faster yous business coming year say incredibly bullish yous business look outperform work least lrp think competitive system aid highly confident offer product multiple different reason believe product special space kevin alluded little bit earlier around bluetooth connectivity one give example someone pump talk phone directtowatch application product one else offer one think population really need deserves quite frankly technology manage diabetes believe differentiator meaningful differentiator going forward add million million year compiling system feel highly confident sit front physician sit front endocrinologist sit front parent child need aid system feel confident choice continue battle make sure message continues go think international book business continue feel confident even post launch competitive system incredibly well thereoperatorwe take next question matt taylor jefferies line openmatt taylor stifel financial corp analyst hi thanks taking question hoping could update u cadence data could expect see year around mentioned glp data could come investigator also stelo going see anything upcoming conference launchkevin sayer chairman president chief executive officer kevin take really need clinical trial stelo far getting product approved lot data use continuous glucose monitoring particularly dexcom system type diabetes world published investigator course next several month reference talk know good idea data come seen study patient better outcome healthier end saving system money outcome hoping drive stelo time respect glps list study ongoing large study cgm element expect study published demonstrate thing talked use cgm glp provides better result study without study published time control investigator expect good data course yearoperatorwe take next question travis steed bank america line opentravis steed bank america merrill lynch analyst hey thanks question guess wanted understand little bit kevin could give clarity think reimbursement pathway stelo could look next couple year think needed open reimbursement product think would look would done traditional way think could done kind oneoff like level program unitedhealthcarekevin sayer chairman president chief executive officer goal traditional time said earlier launch product cash pay product cash pay option cash pay people get purchase product accumulate data user time accumulate data clinical trial see ultimately build case reimbursement product think time certainly expect go cm people type diabetes insulin covered point time group goal spend le money healthcare system one technology enables outcome nature see traditional working payer various government agency time program continue support happy support partner think time need traditional reimbursement path partnership relationship way top continue develop tool around stelo first generation launch going first pas app numerous iteration course first month product really make much inviting engaging product lead people better experience stay tuned say front next month going excitingoperatorand take next question joanne wuensch citigroup line openjoanne wuensch citi analyst good afternoon nice quarter couple question two related one sort give u guidance tax think net interest expense one strike somewhat interesting think lrp operating margin second quarter row bypassed number still right number thank youjereme sylvain chief financial officer sure yeah start tax think year kind dropped closer range necessarily guide year year tax goal course next three five year get low would expect continue come every year grow tax structure put place term net interest income one bit difficult one given interest rate going go time pretty straightforward cash interest cost pretty low given convert basically take look cash balance sheet multiply get would year keep updated interest rate change time way think operating margin perspective gave lrp point valid take look guide year gross margin hold true gross margin absolutely belief already margin absolutely understand mathematics mean ahead ahead lrp necessarily willing update point come forward update point future think good thing done lot work around joanne around getting lean making sure drive leverage business great news ahead good spot continue one maybe caveat think important note year think asked question little bit year year making good investment year organization launching stelo talked significant investment business certainly lot work around sale force recall year ago work around took step back margin going still step forward going go direct japan year another thing making investment work kevin referenced around clinical work around continuing improve product going make investment still deliver expansion operating margin think go show building lever think see building rely u longer term continue drive businessoperatorand take next question matthew obrien piper sandler line openmatthew obrien piper sandler analyst good afternoon thanks taking question looking domestic performance clear acceleration back half twoyear stacked basis wondering specifically basal helping look like much maybe basis point acceleration primary contributor domestic acceleration think term basal contribution topline year inflecting right far basal adoption go cgm state thanksjereme sylvain chief financial officer yeah good question let maybe give color thinking guidance see performance back half year lot accurate sensor launching g form factor course basal coverage think see sharetaking look script data taking share sensor advanced sensor market driver taking share within space basal contributor question category expands take share within category contribute overall number right basal contributor much u taking share category expansion think contributor think talked little bit adoption rate basal total adopting back half year around per year per annum basis guide assumes think assume case longrange plan like per year seeing basal going faster longrange plan great continue take share category grows little faster expected help contribute longer haul hopefully give context seeing basal absolutely contributor want overstate fact though basal quite frankly intensive insulin business continue really really well see u taking share wellkevin sayer chairman president chief executive officer would add jeremes comment matt look second half year g rolled direct correlation g launching acceleration growth really important event thing consequence saw support yous respect field sale expansion need spend time physician familiar technology would past said call earlier call somebody win well need call needed foot street voice given acceleration saw good thing saw happen second half year flow together nicelyoperatorwell take next question margaret andrew william blair line openmargaret andrew william blair company analyst hey good afternoon guy thanks taking question wanted maybe spin back noninsulin kind run market model noninsulin adoption seems meaningfully increased probably well certainly market last couple year number probably perfect maybe market million user yous could get year pretty sizable amount guess one meaningful patient add dexcom already drove going back stelo guidance million per year obviously throw assumption around asp patient add regardless input pretty quickly get million plus sale pretty meaningful chunk chain guess correct could right wrong much could incremental initial lrp provided thankskevin sayer chairman president chief executive officer jereme probably get detail part business today margaret noninsulin user product plan actually cover noninsulin user cgm seen wonderful experience also aggressive cash pay program cash pay program nonetheless noninsulin user access product traditional distribution channel outside pharmacy outside traditional dme individual purchased cgm use noninsulin front well continue support program remarkable chunk business tremendous driver growth grown significant percentage look going forward certainly gave guidance committed certainly forecast guided committed learning really interested number like million like talking positioned right product respect pricing launch product going tremendous flexibility cash pay program labeled current population reimbursement reimbursed product believe flexibility grow growing profitably day product going market lower cog developing lot thing around roll see really changing business model serve type individual versus served point time going offer different experience definitely meet need across board bullish time could big number planning onoperatorwell take next question jayson bedford raymond james line openjayson bedford raymond james analyst good afternoon gross margin think came last year thinking gross margin would lower second half guessing revenue level play part outside price mix weighs gross margin related question encouraging comment malaysia think alluded point see malaysia g starting positive impact gross marginjereme sylvain chief financial officer hey jayson yeah thanks question last year made assumption margin looked like assumption g g transition range assumption assumption g g transition would take place perhaps little bit earlier timing aid system available market coverage go time took little bit longer result outperformed margin get back g cost le make g today still majority user legacy base still sit g system launch tandem controliq integrated g obviously limited launch omnipod coming back half q obviously launch sometime later year believe base start move quicker take place jason shift lower cost highercost product weighing start year hence margin go go back half year assuming base transition model show course year equilibrium balance tilt favor g put u position exiting year g give update base year progress lower g within point accretive would exit rate leading course bodes well move beyond big driver base transition cost kind equilibrium thought going happen back half take place outperformed result probably going take place first half operatorand take next question plovanic canaccord genuity line openwill plovanic canaccord genuity analyst great thanks taking question congratulation quarter kind followup trying get color granularity possible look growth business kind matt obriens question contribution basal hypo intensive type kind shifting order day basal hypo intensive type really new patient growth think cadence continue move forward thanksjereme sylvain chief financial officer yeah mean think least main contributor new patient least revenue new patient still going sit intensive insulin type type insulinintensive patient still combination two make majority new revenue course year basal catching basal nice job catching still part core business still actually driving underlying business time expect basal given larger population well give update get beyond get closer incredibly bullish longterm opportunity basal think least core business actually still driving lot growth obviously longerterm opportunity basal point hypo quite frankly still low contributor stelo kind coming online well real opportunity beyondoperatorwe take next question michael polark wolfe research line openmichael polark wolfe research analyst good afternoon thank want ask followup kevin response prior question day timing heard provide lot color filed see path approval kind seems like thought stelo kind appetizer year day maybe broader rollout want asking pin timing year broader transition day could affected might testing innovation take little longerkevin sayer chairman president chief executive officer would like go fast possible time frame would yesterday stelo day primer learn gather data user use particularly current sensor configuration go technology change making dial feature going put final product get pivotal trial started go learning every day position like g submitting entire new system completely new hardware new feature new manufacturing line new supplier new everything day product built platform current g built time finishing pivotal filing going near intent difficult last product thing security bluetooth stuff worked issue already right really refining science getting day getting reliability quality level patient expect u view extremely think reasonable assumption going give end date many variable certainly headed path along type speed see land give update along way filing thing starting thing important u getting thing done milestone well keep posted areoperatorwe take next question chris pasquale nephron line openchris pasquale nephron research analyst thanks congrats quarter wanted ask couple question dexcom one progress think said expected account international new patient start curious ended portion new patient start expect jereme sylvain chief financial officer sure chris thanks question yes thought going third patient start outside yous closer quarter new patient start little bit behind tender took little bit time get still really good year u little bit behind started year least expectation year expect bigger contributor percentage think last year certainly case g form factor excited obviously coming g form factor four country already launched expectation bit bigger percentage necessarily given number expect bigger team want bigger percentage new patient outside yous operatorwe take next question josh jennings td cowen line openjosh jennings td cowen analyst hi good evening thanks taking question hoping ask followup type hypo noninsulin hypo indication coverage think would move fast type basal think guy talked bigger patient opportunity yous type basal patient opportunity anything bottleneck term penetrating indication see deeper penetration going forward thanks lotjereme sylvain chief financial officer yeah thanks josh area candor gone knew going bit challenge big opportunity going take little bit time awareness getting front physician letting folk know hey look hypo event qualify way document certainly slower basal real material contributor know however teri chief commercial officer team focused getting word making sure folk understand suffering hypo event technology help help change qualify reimbursement working messaging making sure get understand event taking place believe challenge understanding identify took place get front folk working good data around making sure making physician serving patient aware requirement documentation qualify reimbursement work done team working intently making sure arm sale force arm community information needed help grow faster think big opportunity u think opportunity going take little bit longer penetrate point think driver driver little bit certainly opportunity think going continue slow roll longer haul think contributor time meaningfulkevin sayer chairman president chief executive officer would add feed sale force investment making state need educate physician patient get population people positive outcome space go back doctor conversation start taking place becomes easier lot seeding needed foot street thatoperatorand take next question mike kratky leerink partner line openmike kratky leerink partner analyst hi everyone thanks taking question one clarifying one basal previously talked framing penetration within basal population relative trajectory saw insulinintensive type patient would characterize comparison based today also looking next yearsjereme sylvain chief financial officer sure yeah longterm guide talked basal effectively six seven point adoption percentage total population yous start yous internationally coverage work coverage opportunity talked lrp first couple quarter saw mirror question point say mirroring type intensive penetration rate guide least assumes middle two got couple quarter belt positive also want make sure prudent come guidance assumed penetration rate course obviously mirror saw back half opportunity outperform clearly tracking ahead lrp think positive signal think business total guidance percent penetration hopefully help youoperatorwe take next question steve lichtman oppenheimer line opensteve lichtman oppenheimer company analyst thank good evening guy kevin mentioned earlier question different business model stelo think gotomarket could look like dexcom one directtopatient feel need make significant investment backoffice support denominator really expand go large noninsulin groupkevin sayer chairman president chief executive officer great question pertinent topic discussion meeting within wall company much evaluating efficient way serve large patient group patient group may interact differently u insulin time build model looking distribution model appear different today efficiently get product people starting cash pay give u opportunity thing little different done past stay tuned thoughtful question much line everything going every dayoperatorwe take final question matt miksic barclays line openmatt miksic barclays analyst hey great thanks much squeezing one followup margin kind mix drive g bigger part business mentioned think understand ramping g volume improving gross margin profitability product line time wondering could share maybe think long term like word g profitable g profitable rather maturity line g exceeds stelo trail g dexcom one g kind trail maybe sense directionally headed intermediate long term would super helpful drive volume thanks muchjereme sylvain chief financial officer yeah maybe talk thinking cost product think kind make call think margin perspective maybe comment little bit service model think also important help operating margin think g product today cost g eventually expect course year flip kind get model kind bent kind laid expect get sensor irrespective whether day exit lrp early give kind feel get cost sensor sensor hardware cost whether stelo whether dexcom one whether gseries support model software support rd investment course service model ultimately change think work put gseries gseries highest reimbursement also highest service model investment software otherwise dexcom one little bit different service model thus able reduce burden associated warranty support cost play stelo day form factor helpful gross margin perspective think time think way think cost profile launched price stelo point necessarily give specific margin point otherwise maybe pretty obvious thinking time come think help align model think real opportunity think day day product starting stelo make way dexcom one gseries time lever real opportunity product line continue drive profitability think lever across hope give context realize giving pl one least give context hardware cost differentiate opex cost service model course day wearing oneoperatorand lady gentleman time would like turn call back mr kevin sayer closing remarkskevin sayer chairman president chief executive officer thank much easy earnings call talk percentage margin future technology financial guidance competitor whole host important engaging topic wrap today really want focus truly remarkable year history let u review number million organic revenue growth billion ebitda new customer active user base standing plant asia without missing beat course launching g product world bestinclass technology foundational fundamental type accomplishment happen without exceptional people going beyond close want thank guess dexcom employee around world incredibly well done thanks everybodyoperatoroperator signoff duration minutescall participantssean christensen head investor relationskevin sayer chairman president chief executive officerjereme sylvain chief financial officerrobbie marcus jpmorgan chase company analystdanielle antalffy ubs analystlarry biegelsen well fargo security analystmathew blackman stifel financial corp analystmarie thibault btig analystjeff johnson robert w baird company analystmatt taylor stifel financial corp analysttravis steed bank america merrill lynch analystjoanne wuensch citi analystmatthew obrien piper sandler analystmargaret andrew william blair company analystjayson bedford raymond james analystwill plovanic canaccord genuity analystmichael polark wolfe research analystchris pasquale nephron research analystjosh jennings td cowen analystmike kratky leerink partner analyststeve lichtman oppenheimer company analystmatt miksic barclays analyst dxcm analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool recommends dexcom motley fool disclosure policy